The Conditions Under Which Piracetam Is Used and the Factors That Can Improve National Institute of Health Stroke Scale Score in Ischemic Stroke Patients and the Importance of Previously Unnoticed Factors From a Hospital-Based Observational Study In...

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Jan 24

PMID 30669522

Citations 1

Authors

Shu-Yi Chen

Jai-Wen Liu

Yu-Hsun Wang

Jing-Yang Huang

Shiuan-Chih Chen

Shun-Fa Yang

Po-Hui Wang

Affiliations

Soon will be listed here.

Abstract

This study aimed to explore the associations of piracetam use and the clinical characteristics of NIHSS (National Institute of Health Stroke Scale) changes-the importance of which, as prognosis related factors, was previously unnoticed-and analyze the associations of piracetem with NIHSS changes by stratifying clinical characteristics. This observational retrospective study was conducted by enrolling patients based on 2483 stroke registration data cohorts from a 1200-bed regional Tungs' Taichung MetroHarbor Hospital, located in central Taiwan from 1 January 1 2011 to 31 December 2015. Patients were excluded if they had intravenous a thrombolytic agent within 3 hours of symptoms onset ( = 49), incomplete or erroneous NIHSS scores ( = 953), or transient ischemia stroke ( = 130). Logistic regression model was applied for associating piracetam treatment and clinical characteristics with NIHSS score changes between admission and discharge, and subgroup analysis to assess the conditions under which piracetam can be used. Multivariate analysis revealed NIHSS scores improvement in atrial fibrillation, large-artery atherosclerosis, underweight, current smoker, ex-smoker, and piracetam. Subgroup analysis showed piracetam is beneficial in the following: age ≥75 years olds, males, those of normal weight, those who are obese, ex-smokers, those with hypertension, dyslipidemia, those without diabetes mellitus, nor atrial fibrillation. The selection of the conditions under which piracetam treatment should be given, and clinical characteristics, is important for NIHSS improvement of ischemic stroke patients in Taiwan.

Citing Articles

Metabolic Reprogramming: Strategy for Ischemic Stroke Treatment by Ischemic Preconditioning.

Liang J, Han R, Zhou B Biology (Basel). 2021; 10(5).

PMID: 34064579 PMC: 8151271. DOI: 10.3390/biology10050424.

References

. Guidelines for intensive care unit admission, discharge, and triage. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med. 1999; 27(3):633-8. View

Evers S, Grotemeyer K . Piracetam and platelets--a review of laboratory and clinical data. Pharmacopsychiatry. 1999; 32 Suppl 1:44-8. DOI: 10.1055/s-2007-979236. View

Ricci S, Celani M, Cantisani T, Righetti E . Piracetam in acute stroke: a systematic review. J Neurol. 2000; 247(4):263-6. DOI: 10.1007/s004150050581. View

Kessler J, Thiel A, Karbe H, Heiss W . Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke. 2000; 31(9):2112-6. DOI: 10.1161/01.str.31.9.2112. View

Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N . Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke. 2000; 31(11):2616-22. DOI: 10.1161/01.str.31.11.2616. View

Tortiglione A, Minale M, Pignataro G, Amoroso S, DiRenzo G, Annunziato L . The 2-oxopyrrolidinacetamide piracetam reduces infarct brain volume induced by permanent middle cerebral artery occlusion in male rats. Neuropharmacology. 2002; 43(3):427-33. DOI: 10.1016/s0028-3908(02)00093-x. View

Johnston S, Leira E, Hansen M, Adams Jr H . Early recovery after cerebral ischemia risk of subsequent neurological deterioration. Ann Neurol. 2003; 54(4):439-44. DOI: 10.1002/ana.10678. View

Bruno A, Saha C, Williams L . Using change in the National Institutes of Health Stroke Scale to measure treatment effect in acute stroke trials. Stroke. 2006; 37(3):920-1. DOI: 10.1161/01.STR.0000202679.88377.e4. View

Winnicka K, Tomasiak M, Bielawska A . Piracetam--an old drug with novel properties?. Acta Pol Pharm. 2006; 62(5):405-9. View

10.

Marler J . NINDS clinical trials in stroke: lessons learned and future directions. Stroke. 2007; 38(12):3302-7. DOI: 10.1161/STROKEAHA.107.485144. View

11.

Wheble P, Sena E, Macleod M . A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke. Cerebrovasc Dis. 2007; 25(1-2):5-11. DOI: 10.1159/000111493. View

12.

Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N . Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009; 8(12):1095-102. DOI: 10.1016/S1474-4422(09)70264-9. View

13.

Malykh A, Sadaie M . Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010; 70(3):287-312. DOI: 10.2165/11319230-000000000-00000. View

14.

Chiang C, Wang T, Li Y, Lin T, Chien K, Yeh H . 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc. 2010; 109(10):740-73. DOI: 10.1016/S0929-6646(10)60120-9. View

15.

Fritz C, Morris P, Richler J . Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen. 2011; 141(1):2-18. DOI: 10.1037/a0024338. View

16.

Siegler J, Boehme A, Kumar A, Gillette M, Albright K, Martin-Schild S . What change in the National Institutes of Health Stroke Scale should define neurologic deterioration in acute ischemic stroke?. J Stroke Cerebrovasc Dis. 2012; 22(5):675-82. PMC: 5535077. DOI: 10.1016/j.jstrokecerebrovasdis.2012.04.012. View

17.

Ricci S, Celani M, Cantisani T, Righetti E . Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev. 2012; (9):CD000419. PMC: 7034527. DOI: 10.1002/14651858.CD000419.pub3. View

18.

Echouffo-Tcheugui J, Woodward M, Kengne A . Predicting a post-thrombolysis intracerebral hemorrhage: a systematic review. J Thromb Haemost. 2013; 11(5):862-71. DOI: 10.1111/jth.12186. View

19.

Stone N, Robinson J, Lichtenstein A, Merz C, Blum C, Eckel R . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 129(25 Suppl 2):S1-45. DOI: 10.1161/01.cir.0000437738.63853.7a. View

20.

Emberson J, Lees K, Lyden P, Blackwell L, Albers G, Bluhmki E . Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014; 384(9958):1929-35. PMC: 4441266. DOI: 10.1016/S0140-6736(14)60584-5. View